Cencora (COR) Stock Price & Analysis

COR$359.03+10.31 +2.96%
Medical - DistributionLarge Cap
Compare
Market cap$68.51BEnterprise value$73.94BRevenue (TTM)$337.40BMarket positionTop 25%

Score

42
Bearish
Value
38
Quality
42
Growth
47

AI Analysis

Snapshot

Cencora doesn’t screen as a clean setup today — Stocklytics 42/100 leaves more to prove. Under the hood: P/E 19.7, plus revenue compounding ~9% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

38
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

47
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

42
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Cencora, Inc. (COR) last printed $359.03. Equity value is $68.51B. Trailing earnings multiple 19.67. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2017201820192020202120222023202420252026
$153.14B$167.94B$179.59B$189.89B$213.99B$238.59B$262.17B$293.96B$321.33B$337.4B

About

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

Cencora (COR) Stock Price & Analysis

COR price $359.03 +10.31 +2.96%

Ticker
COR
Price
$359.03
Change
+10.31 +2.96%
Market cap
$68.51B
P/E
19.67
Forward P/E
18.17
Dividend yield
0.68%
Beta
0.58
Sector
Healthcare
Industry
Medical - Distribution
Stocklytics score
42
Value
38
Quality
42
Growth
47

Stocklytics score rationale: value 38, quality 42, growth 47.

AI Score 75. Cencora, Inc. has a market cap of $67.55 billion and a price of $354, indicating a solid valuation with a price-to-earnings ratio of approximately 19.7

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener